Archive

Abstract

A mental illness called schizophrenia is characterised by disturbances in cognition, perception, emotional responsiveness, and social relations. Around 24 million individuals, or 1 in 300 persons (0.32%), worldwide suffer from schizophrenia. For men, this incidence is 1 in 222 (0.4%). Here, a person's capacity for thought, emotion, and behaviour is impacted. Memory loss and attention problems could also be present. According to neurological theory, imbalance of certain neurotransmitters, including: Gamma-aminobutyric acid (GABA) expression levels in the prefrontal cortex, an excess of dopamine, decreased glutamate levels in the cerebrospinal fluid, or decreased serotonin levels Schizophrenia is thus the most prevalent mental disease of our time, causing severe disruptions for those who have it and consuming a sizable percentage of the health system's limited resources. In this essay, the most current research on introduction, etiology, symptoms, and remedies is reviewed. Researching this disease ran into some methodological issues, which are addressed. The results of therapies available for this condition have improved, but whether a patient gets these treatments may rely on the services that the local community is willing to provide.

Keywords

Schizophrenia, Emotional responsiveness, Neurobiological theory, Neurotransmitter, Dopamine, Prefrontal cortex

Reference

  1. Social elements in schizophrenia. Hooley JM. Current Directions in Psychological Science, August 2010, 19, 238–242.
  2. Emotion processing and its link to social performance in people with schizophrenia, Hooker C et al. Research in psychiatry. 2002 Sep 15;112(1):41-50.
  3. "Social skills and social functioning," by Mueser et al. (1998
  4. "Prevalence and stability of social skill deficits in schizophrenia," by Mueser et al. Research on schizophrenia 5.2 (1991): 167–176
  5. "Gender, social competence, and symptomatology in schizophrenia: a longitudinal analysis," Mueser et al.  138 in Journal of Abnormal Psychology 99.2 (1990).
  6. The evolution of interpersonal interactions in people with schizophrenia, Nisenson et al. 111–125 in Psychiatry 64.2 (2001).
  7. Social skills, perceived beauty, and symptoms are interpersonal variables that contribute to the stigma of schizophrenia, according to Penn et al. Research on schizophrenia 45.1-2 (2000): 37–45
  8. "Neurocognitive and social cognitive predictors of interpersonal skill in schizophrenia," by Pinkham et al. 167–178 in Psychiatry Research 143.2-3 (2006).
  9. Zhu, et al. Social performance and recognition of social signals are impaired in Chinese individuals with schizophrenia. Clinical Neurosciences in Psychiatry, 61, 149–158
  10. E.L. Messias et al. schizophrenia epidemiology: a summary of research and urban legends. 2007 Sep 1;30(3):323–338 in Psychiatric Clinics of North America.
  11. A review of schizophrenia susceptibility and risks: Beyond the two strike theory, Davis et al. (2016) 185–194 in Neuroscience & Biobehavioral Reviews 65.
  12. "Schizophrenia: overview and treatment options," Pharmacy and Therapeutics 39.9 (2014): 638, by Patel et al.
  13. "Diagnostic and statistical manual of mental disorders," Carter, Marcia Jean. Journal of therapeutic leisure 48.3 (2014): 275.
  14. "Ferri's Differential Diagnosis: A Practical Guide to the Differential Diagnosis of Symptoms, Signs, and Clinical Disorders," by Jane K. Case, 14. Elsevier, 2006. Mayo Clinic Proceedings, Vol. 81, No. 10.
  15. Differential diagnostic of borderline personality disorder, Joel Paris. Clinical Psychiatry 41.4 (2018): 575–582.
  16. The diagnostic notion of schizophrenia: its background, development, and possibilities, by Assen Jablensky, 16. Clinical neurobiology discussions (2022).
  17. "Psychosis prevalence and physical, metabolic, and cognitive co-morbidity: data from the second Australian national survey of psychosis," by Morgan, V. A., et al. 2146-2176 in Psychological Medicine 44.10 (2014).
  18. E. Jääskeläinen et al., "A Systematic Review and Meta-Analysis of Recovery in Esquizophrenia." 39.6 (2013): 1296–1306 Schizophrenia Bulletin.
  19. Self-reported physical activity levels and exercise recommendation practises of conference attendees at the 2017 Royal Australian and New Zealand College of Psychiatrists (RANZCP) meeting, by Fibbins et al. 2020: 565-572 in Journal of Mental Health, 29.5.
  20. "Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial," by Girgis et al. 281-288 in The British Journal of Psychiatry, Vol. 199.4, 2011.
  21. "Clozapine as a first treatment for schizophrenia," by Woerner et al. (2003): 1514–1516 in American Journal of Psychiatry 160.8.
  22. "Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment," McEvoy, Joseph P., et al. (2006): 600–610 in American Journal of Psychiatry 163.4.
  23. Javier Sanz-Fuentenebro et al. Results of a one-year random comparison of clozapine and risperidone in the treatment-naive first incident of schizophrenia. Research on schizophrenia 149.1-3 (2013): 156–161.
  24. Atypical antipsychotics and weight gain: a comprehensive review, Taylor, D. M. and McAskill, 24. (2000): 416-432 in Acta Psychiatrica Scandinavica 101.6.
  25. 25. Sahni S, et al. A pilot trial comparing clozapine and risperidone in the management of first-episode schizophrenia. 2016 November;144(5):697 The Indian Journal of Medical Research.
  26. 26. "Suicidal risk during treatment with clozapine: a meta-analysis," by John Hennen and Ross J. Baldessarini. Research on schizophrenia 73.2-3 (2005): 139–145.
  27. "Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study," Muscatello, Maria Rosaria A., et al. Research on schizophrenia 127.1-3 (2011): 93–99.
  28. "Effects of cognitive behavioural therapy on work outcomes in vocational rehabilitation for participants with schizophrenia spectrum disorders," by Paul H. Lysaker et al., 28. Research on schizophrenia 107.2-3 (2009): 186–191.
  29. Individual placement and support: an evidence-based strategy for assisted work. Drake et al. 2012; Oxford University Press.
  30. "Supported employment for adults with severe mental illness," Kinoshita et al. Database of Systematic Reviews Cochrane 9 (2013).
  31. The unhealthy living of individuals with schizophrenia, by Steve Brown et al. Medical psychology 29.3 (1999): 697–701.
  32. "Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study," by Robin McCreadie et al. Bmj 317.7161 (1998): 784-785.
  33. Weight gain in male teenage schizophrenic inpatients treated with olanzapine is correlated with increased food consumption and poor habitual exercise levels, according to Gothelf et al. 159.6 (2002): 1055–1057 in the American Journal of Psychiatry.
  34. The gluten connection: the link between celiac disease and schizophrenia, 34 Kalaydjian, A. E., et al. 82–90 are included in Acta Psychiatrica Scandinavica 113.2 (2006).
  35. In the postmortem orbitofrontal cortex of individuals with bipolar disorder, there are deficiencies in docosahexaenoic acid and related elevations in the metabolism of arachidonic acid and saturated fatty acids. Research in psychiatry 160.3 (2008): 285-299.
  36. Relationship of low vitamin D levels with positive, negative, and cognitive symptom categories in individuals with first-episode schizophrenia, Graham, K. A., et al. Early Intervention in Psychiatry, 9, 3, 397–405, 2015.
  37. Psychiatry (Edgmont) 2.2 (2005): 31. Strassnig, "Dietary intake of patients with schizophrenia."
  38. Schizophrenia, gluten, and low-carb, ketogenic diets: a case report and literature survey, 38. Kraft. 2009: 1-3; Nutrition & Metabolism 6.1.
  39. "Mortality in people with schizophrenia in rural China," by Mao-Sheng, Ran, et al. (2007) 237–242 The British Journal of Psychiatry, 190.3.
  40. Jamie Joseph et al. published a study titled "Modified Mediterranean diet for enrichment of short chain fatty acids: potential adjunctive therapeutic to target immune and metabolic dysfunction in schizophrenia?" 40.  Neuroscience Frontiers 11 (2017): 155.
  41. "Holistic management of schizophrenia symptoms using pharmacological and non-pharmacological treatment," by Ganguly et al. (2018). Frontiers in Public Health 6: 166.
  42. Results of a 2-year randomised study on the effects of cognitive enhancement treatment on job outcomes in early schizophrenia, Eack et al. 42. Social Work Practice Research 21.1 (2011): 32–42.
  43. "Computerized cognitive training restores neural activity within the reality monitoring network in schizophrenia," by Subramaniam et al. 43. (2012) 842–885 in Neuron 73.4.
  44. Gumley, A., et al. 44. Iacp president's message stefan g. Hofmann, phd primum non necera 47 (2015): 11 "quiet narcissism continued from pg. 9."
  45. "Suicides during pregnancy and 1 year postpartum in Sweden, 1980-2007," by Esscher et al.  462-469 in British Journal of Psychiatry 208.5 (2016).
  46. "Yoga therapy for schizophrenia," by Arun Jha, 46.  (2008): 397-397, Acta Psychiatrica Scandinavica 117.5.
  47. 47. "Development of the beliefs about yoga scale," by Sohl et al. 21.1 (2011): 85–91 International Journal of Yoga Therapy.
  48. "Systematic review of the advantages of physical therapy within a multidisciplinary care approach for people with schizophrenia," Vancampfort et al. 48. 2012;92(1):11–23; Physical Therapy.
  49. David Feifel 49. Is oxytocin a potentially effective therapy for schizophrenia? Neurotherapeutics expert review 11.2 (2011): 157–159.
  50. 50. "Substance use among schizophrenic outpatients: prevalence, course, and relation to functional status." Chouljian, Tandy L., et al. 1995: 19–24, Annals of Clinical Psychiatry 7.1.
  51. The trajectory of schizophrenia over 13 years: a study from the World Health Organization-led International Study on Schizophrenia (ISoS), by Mason et al. 1996: 580-586 in The British Journal of Psychiatry, 169.5.
  52. "Violent and destructive behaviour among the severely mentally ill in rural areas: evidence from Arkansas' community mental health system," by Brian J. Cuffel, 52. Journal of Community Mental Health 30.5 (1994): 495–504.
  53. "Improving treatment adherence in patients with schizophrenia," M. Kane John, 53. Psychiatry Research and Practice 72.9 (2011): 27738.
  54. Wang, among others. "Tobacco increases protection against oxidative stress by overexpressing an Arabidopsis peroxisomal ascorbate peroxidase gene." 725–732, 1999, Plant and Cell Physiology 40.7.
  55. Alcohol and weed use in schizophrenia: impacts of clozapine vs. risperidone, Green, Alan I., et al. Research on schizophrenia 60.1 (2003): 81–85

image
Monali Khatake
Corresponding author

Department of Pharmaceutical Quality Assurance, PRES College of Pharmacy (Women’s), Chincholi, Nashik-422102

image
Vinayak Gaware
Co-author

Department of Pharmaceutical Chemistry, PRES College of Pharmacy (Women’s), Chincholi, Nashik-422102

image
Rahul Khaire
Co-author

Department of Pharmaceutical Chemistry, PRES College of Pharmacy (Women’s), Chincholi, Nashik-422102

image
Charushila Bhangale
Co-author

Department of Pharmaceutical Chemistry, PRES College of Pharmacy (Women’s), Chincholi, Nashik-422102

Monali Khatake*, Vinayak Gaware, Rahul Khaire, Charushila Bhangale, Overview and Treatments of Schizophrenia: A Recent Update, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 4, 153-165. https://doi.org/10.5281/zenodo.7847211

More related articles
Pharmacological Activity Of Tridax Procumbens ...
Rutuja G. Jogdande , Priya R. Kamble, Ashwini Chougule, Jaya Kamb...
Nanotechnology ...
Salunke Yashraj Rajendra , Pawar Vikas Rajendra , Sayyed Afnan ki...
Formulation And Characterization Of Provesicular B...
Akshata Rajesh Shirodker, Rajashree Gude, Suman Harisingh Vishwak...
Formulation Design and characterization of Antifungal Emulgel for Topical Delive...
Pranali R. Gajbhiye, Yogesh N. Gholse, Rahul V. Jadhav, Nitin B. Kohale, ...
An Overview Of Muscular Dystrophy...
Yenkathala Shivani, Grishma Krishnan, Ishu, Aashutosh Sinwal, Aman Saini, Pooja Brahambhatt, ...
Related Articles
Spray: Film Forming System Promising As Transdermal Drug Delivery System...
Madhuri D. Sahane , Maya Y. Gaikwad, Divya S. Gaikar, ...
Design, Synthesis and Pharmacological Evaluation of Novel Pyrimidine Derivatives...
Avinash Patil, Prashant Chavan, Amitkumar Rawal, Kiran Patil, ...
Artificial Neural Network In Pharmaceutical And Cosmeceutical Research ...
Rajput Anamika, Arya Divya, Panshul Chauhan, Atul Dixit, Debaprasad Ghosh, Ashu Mittal, ...
Ozone And Ozonated Oils In Skin Diseases...
Salunke R. Yashraj, Saurabh R. Kharat , Sham Ganesh Ardad , Nimbalkar Vaibhav , Jadhav Anil B. , ...
Pharmacological Activity Of Tridax Procumbens ...
Rutuja G. Jogdande , Priya R. Kamble, Ashwini Chougule, Jaya Kamble, Nilesh Chougule, ...
More related articles
Pharmacological Activity Of Tridax Procumbens ...
Rutuja G. Jogdande , Priya R. Kamble, Ashwini Chougule, Jaya Kamble, Nilesh Chougule, ...
Nanotechnology ...
Salunke Yashraj Rajendra , Pawar Vikas Rajendra , Sayyed Afnan kirmani, Kawade Rajendra madhukar, ...
Formulation And Characterization Of Provesicular Based Drug Delivery System For ...
Akshata Rajesh Shirodker, Rajashree Gude, Suman Harisingh Vishwakarma, Eliska Wendy de Souza, Vishak...
Pharmacological Activity Of Tridax Procumbens ...
Rutuja G. Jogdande , Priya R. Kamble, Ashwini Chougule, Jaya Kamble, Nilesh Chougule, ...
Nanotechnology ...
Salunke Yashraj Rajendra , Pawar Vikas Rajendra , Sayyed Afnan kirmani, Kawade Rajendra madhukar, ...
Formulation And Characterization Of Provesicular Based Drug Delivery System For ...
Akshata Rajesh Shirodker, Rajashree Gude, Suman Harisingh Vishwakarma, Eliska Wendy de Souza, Vishak...